Abbott Laboratories

New York Stock Exchange
Back to all articles
Somewhat Bullish +45

Abbott Laboratories (NYSE:ABT) Shares Gap Up on Strong Earnings

AI-generated analysis

📈 Abbott Laboratories shares gapped up to open at $95.29 after reporting Q3 EPS of $1.31, beating analyst estimates of $1.28.

💰 Revenue for the quarter totaled $12.51 billion, marking a 13.0% increase compared to the same quarter last year.

📊 The company achieved a net margin of 11.65% and a return on equity of 17.65% during the reporting period.

🔮 Q3 2026 EPS guidance is set between $1.38 and $1.46, with full-year FY 2026 guidance ranging from $5.45 to $5.60.

💵 A quarterly dividend of $0.63 per share was announced, resulting in a 2.5% annualized dividend yield for investors.

📉 Analyst price targets were recently lowered by Sanford C. Bernstein ($125 to $110), Evercore ($134 to $120), and UBS Group ($158 to $135).

🏦 Institutional ownership stands at 75.18%, with Norges Bank initiating a new position valued at approximately $2.9 billion.

📈 J. Stern & Co. LLP significantly increased its stake by over 12,000% in the fourth quarter to own nearly 39.3 million shares.

🏢 The company has a market capitalization of $175.41 billion and trades at a P/E ratio of 32.59.

📉 The current consensus price target from MarketBeat is $118.61 with a 'Moderate Buy' rating based on analyst data.

Bullish Signals
  • Abbott Laboratories reported EPS of $1.31, which exceeded the consensus estimate of $1.28 by $0.03.
  • Revenue grew by 13.0% year-over-year to reach $12.51 billion for the quarter.
  • The company maintains a healthy net margin of 11.65% and a return on equity of 17.65%.
  • Institutional investors like Norges Bank initiated new positions, while J. Stern & Co. LLP increased its stake by over 12,000% in the last quarter.
  • The company announced a quarterly dividend of $0.63 per share with a 2.5% yield.
Risk Factors
  • Several major analysts recently lowered their price targets, including UBS Group reducing its target from $158 to $135 and Sanford C. Bernstein cutting it from $125 to $110.
  • Quarterly revenue of $12.51 billion was slightly below the specific analyst expectation of $12.52 billion.
Full Analysis
Abbott Laboratories (NYSE:ABT) shares opened significantly higher, gapping up from a previous close of $89.27 to $95.29 following the release of better-than-expected quarterly earnings. The company reported earnings per share (EPS) of $1.31, surpassing analyst consensus estimates of $1.28 by $0.03. Revenue for the quarter reached $12.51 billion, which was slightly below the specific expectation of $12.52 billion but represented a robust 13.0% year-over-year increase compared to the same period last year. The healthcare giant demonstrated strong profitability metrics with a net margin of 11.65% and a return on equity of 17.65%. Looking ahead, Abbott has provided guidance for the third quarter of 2026 ranging from $1.38 to $1.46 per share in EPS, and full-year fiscal 2026 guidance between $5.45 and $5.60 per share. Additionally, the company announced a quarterly dividend of $0.63 per share, payable on August 17th to shareholders of record as of July 15th. Analyst sentiment remains mixed but generally positive regarding the stock's trajectory. While several major firms including Sanford C. Bernstein, Evercore, UBS Group, and Mizuho recently lowered their price targets in April reports, maintaining 'outperform' or 'buy' ratings, the consensus rating from MarketBeat is currently a 'Moderate Buy' with a target price of $118.61. Institutional ownership remains high at 75.18%, with significant recent buying activity from large investors like Norges Bank and J. Stern & Co. LLP.